From Mechanisms to Therapies: Current Advances and Breakthroughs in Alopecia Areata Immunopathology

The document provides a comprehensive overview of the immunopathology and therapeutic strategies for alopecia areata (AA), an autoimmune condition causing hair loss. It highlights the role of immune cells like CD8+NKG2D+ T cells and cytokines such as IFN-γ in disrupting hair follicle immune privilege. The JAK-STAT pathway is identified as a crucial target, with JAK inhibitors like baricitinib, deuruxolitinib, and ritlecitinib showing significant promise, some receiving FDA approval. Other therapeutic approaches, including Th2 cytokine inhibitors and IL-12/IL-23 inhibitors, have shown mixed results. The document emphasizes the need for further research to refine treatment strategies and explore novel agents, aiming for personalized treatments and improved patient outcomes.